8-K: Taysha TSHA-102 Shows Broad Gains in Rett Syndrome Trial

Taysha Gene Therapies announced new supplemental data from its REVEAL Phase 1/2 trials for TSHA-102 in Rett Syndrome, showing 100% of patients achieved multiple functional gains.

Summary

• Taysha Gene Therapies presented new supplemental data analysis from Part A of its REVEAL Phase 1/2 adult/adolescent and pediatric trials evaluating TSHA-102 in females with Rett syndrome at the 54th Child Neurology Society (CNS) Annual Meeting.
• The pivotal trial primary endpoint of gaining/regaining one natural history defined developmental milestone was achieved by 100% of the 10 patients in Part A.
• A total of 22 developmental milestones were achieved across the 10 patients, reflecting meaningful functional gains impacting activities of daily living.
• New supplemental analysis of validated, structured efficacy scales provided supportive evidence of additional functional gains, with 100% of patients demonstrating multiple skill gains/improvements outside the natural history defined developmental milestones.
• A total of 165 additional skills/improvements were achieved across the 10 patients, further supporting the broad and consistent therapeutic impact of TSHA-102 on functional abilities and activities of daily living.
• TSHA-102 is a self-complementary intrathecally delivered AAV9 investigational gene transfer therapy designed as a one-time treatment to address the genetic root cause of Rett syndrome by delivering a functional MECP2 gene using miRARE technology.

Sentiment

Score: 9

Explanation: The clinical data presented for TSHA-102 in Rett syndrome is overwhelmingly positive, demonstrating a 100% response rate on the primary endpoint and significant additional functional gains across all patients. This suggests a strong therapeutic effect in a disease with high unmet medical need, positioning the company favorably for future development and potential commercialization.

Positives

• 100% response rate across all 10 patients in Part A for the pivotal trial primary endpoint of gaining/regaining one natural history defined developmental milestone.
• Supplemental analysis showed 100% of patients demonstrated multiple additional functional skill gains/improvements across core domains (communication, fine motor, gross motor, autonomic function).
• A total of 22 developmental milestones and 165 additional skills/improvements were achieved across the 10 patients post-TSHA-102.
• The likelihood of achieving these developmental milestones without treatment is very low (0% to <6.7%) based on natural history data.
• TSHA-102 has received multiple expedited regulatory designations, including Breakthrough Therapy, Regenerative Medicine Advanced Therapy (RMAT), Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the FDA, as well as Orphan Drug designation from the European Commission and Innovative Licensing and Access Pathway (ILAP) designation from the MHRA.

Risks

• The reproducibility and durability of any favorable results initially seen in patients dosed to date in clinical trials, including with respect to functional milestones, are not guaranteed.
• The potential of TSHA-102 and Taysha's other product candidates to positively impact quality of life and alter the course of disease in patients is subject to uncertainties.
• There are risks associated with Taysha's research, development, and regulatory plans for its product candidates, including the timing of initiating additional trials, reporting data from clinical trials, and making regulatory submissions.
• There is no guarantee that these product candidates will receive regulatory approval from the FDA or equivalent foreign regulatory agencies.
• If approved, there is no certainty that these product candidates will be successfully distributed and marketed.
• The potential market opportunity for Taysha's product candidates may not materialize as expected.

Future Outlook

Taysha anticipates that TSHA-102 has the potential to positively impact quality of life and alter the course of Rett syndrome. The company plans to continue its research, development, and regulatory activities for TSHA-102, including further clinical trials and regulatory submissions, with the aim of achieving regulatory approval and successful market distribution.

Management Comments

• "Systematic evaluation criteria were applied to REVEAL Part A data to assess the broad therapeutic impact of TSHA-102 on functional aspects of Rett syndrome, including the pivotal trial primary endpoint of developmental milestone achievements not expected without treatment based on natural history data, assessed by independent raters through video-evidenced evaluation. Importantly, this approach enabled the reliable and objective measure of TSHA-102's efficacy." Elsa Rossignol, M.D., FRCP, FAAP, Associate Professor in Neuroscience and Pediatrics at the Université de Montréal, Director of the Rett Multidisciplinary Clinic of the CHU Sainte-Justine and a Principal Investigator of the REVEAL trials.
• "The new supplemental analysis of Part A data further underscores the potential consistency and breadth of TSHA-102's impact across the core domains of Rett syndrome, including communication, fine motor, gross motor and autonomic function. In addition to the developmental milestones achieved across the treatment cohort in Part A, patients consistently gained additional skills and improvements across core disease characteristics. We believe this reinforces the potential therapeutic impact of TSHA-102 on activities of daily living that are important to caregivers and clinicians." Sukumar Nagendran, M.D., President and Head of R&D of Taysha.

Industry Context

The gene therapy landscape for rare neurodevelopmental disorders, particularly those affecting the central nervous system like Rett syndrome, represents a significant area of unmet medical need. Taysha's TSHA-102, an AAV9-based gene therapy, is positioned to address the genetic root cause of Rett syndrome, a condition currently lacking disease-modifying therapies. Positive clinical data in this space can be transformative, offering hope for patients and caregivers where current treatments are largely symptomatic. The use of miRARE technology to regulate MECP2 expression is a notable approach to mitigate potential overexpression risks, a common challenge in gene therapy.

Stakeholder Impact

• Shareholders: Highly positive clinical data for a lead asset is likely to increase investor confidence and potentially drive share price appreciation.
• Patients and Caregivers: The data offers significant hope for a disease-modifying treatment for Rett syndrome, which currently lacks such options, potentially improving quality of life.
• Clinicians: The positive results provide evidence for a potential new therapeutic option for managing Rett syndrome, addressing core disease characteristics.
• Regulatory Bodies: The strong data, coupled with existing expedited designations, could facilitate a smoother and faster regulatory review process.

Key Dates

Recommendation

The clinical data for TSHA-102 in Rett syndrome is exceptionally strong, demonstrating a 100% response rate on the primary endpoint and broad functional improvements across all treated patients. This represents a significant de-risking event for the company's lead asset in a rare disease with a high unmet medical need and no approved disease-modifying therapies. The consistency and breadth of the observed gains, coupled with multiple expedited regulatory designations, suggest a high probability of successful development and potential market entry. This positive clinical update significantly enhances the investment thesis for Taysha Gene Therapies.

Keywords

Taysha Gene Therapies, TSHA-102, Rett Syndrome, Gene Therapy, Clinical Trial, Phase 1/2, CNS disorders, AAV9, MECP2, Neurodevelopmental disorder, Biotechnology